Weak Fundamental Momentum Drags Applied Therapeutics Inc (APLT) Upper

Applied Therapeutics Inc (NASDAQ:APLT) has a beta value of 1.99 and has seen 2.21 million shares traded in the last trading session. The company, currently valued at $583.92M, closed the last trade at $5.11 per share which meant it gained $0.44 on the day or 9.42% during that session. The APLT stock price is -83.76% off its 52-week high price of $9.39 and 76.91% above the 52-week low of $1.18. The 3-month trading volume is 837.71K shares.

Applied Therapeutics Inc (NASDAQ:APLT) trade information

Sporting 9.42% in the green in last session, the stock has traded in the green over the last five days, when the APLT stock price touched $5.11 or saw a rise of 5.02%. Year-to-date, Applied Therapeutics Inc shares have moved 52.54%, while the 5-day performance has seen it change 19.39%. Over the past 30 days, the shares of Applied Therapeutics Inc (NASDAQ:APLT) have changed 10.61%.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Applied Therapeutics Inc (APLT) estimates and forecasts

Figures show that Applied Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have gained 91.39% over the past 6 months, with this year growth rate of 22.54%, compared to 15.30% for the industry.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -8.72% over the past 5 years.

APLT Dividends

Applied Therapeutics Inc is expected to release its next earnings report in July this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.